Accelerated Repair Stack
BPC-157 + TB-500 — the classic synergistic repair protocol.
TB-500 (Thymosin Beta-4) promotes actin polymerisation and long-range cell migration, while BPC-157 drives local angiogenesis and growth factor signalling. Together they cover both systemic and localised repair mechanisms.
What's in this stack
Research Protocol
- BPC-157: 250–500 mcg twice daily
- TB-500: 5 mg twice weekly (loading), then 5 mg weekly
- KPV: 500 mcg daily
Ready to start your Accelerated Repair Stack research?
Each compound ships COA-verified, >98% purity, cold-packed for stability.
Frequently Asked Questions
What is the most studied peptide for tissue repair research?
BPC-157 (Body Protection Compound-157) has the most extensive published research on soft tissue repair, with studies covering tendon, ligament, muscle, and gut lining recovery mechanisms.
How does BPC-157 differ from TB-500 in recovery research?
BPC-157 primarily drives local angiogenesis and growth factor signalling at the injury site, while TB-500 (Thymosin Beta-4) promotes systemic cell migration via actin polymerisation. Research suggests they act synergistically through complementary mechanisms.
How long are recovery peptide research cycles typically run?
Published research protocols typically run 8–12 weeks for recovery-focused peptides, followed by a 4-week washout period before reintroduction.
Are recovery peptides available in oral capsule format?
BPC-157 and KPV have both been studied in oral formats. Rainbow Peptide offers BPC-157 in capsule (500 mcg) for researchers preferring non-injectable administration.
For research use only. Not intended for human consumption. Must be 18+.